CARBETOCIN VERSUS RECTAL MISOPROSTOL FOR MANAGEMENT OF THIRD STAGE OF LABOR IN WOMEN AT LOW RISK OF POSTPARTUM HEMORRHAGE
Status:
Completed
Trial end date:
2019-05-30
Target enrollment:
Participant gender:
Summary
150 pregnant women admitted for spontaneous, induced or augmented vaginal delivery and
categorized as low risk for postpartum hemorrhage (PPH) were divided randomly into two
groups. Carbetocin group (C) received 1 ampoule of Carbetocin (100 μg/ml) (Pabal®,
Draxis/Multipharma, Egypt, under license from DRAXIS PHARMA-Canada) added to 10 cc saline and
given IV after the delivery of the baby. Misoprostol group (M) received 2 rectal misoprostol
tablets (800 μg) (Misotac; SIGMA Pharm, Cairo, Egypt) after the delivery of the baby. Blood
samples were tested to measure hemoglobin levels upon admission to the labor room and 12
hours after delivery